Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

被引:242
作者
Serrano, Beatriz [1 ]
Alemany, Laia [1 ,2 ]
Tous, Sara [1 ]
Bruni, Laia [1 ]
Clifford, Gary M. [3 ]
Weiss, Thomas [4 ]
Xavier Bosch, Francesc [1 ]
de Sanjose, Silvia [1 ,2 ]
机构
[1] Hosp Llobregat, IDIBELL, CERP,Unit Infect & Canc UNIC, ICO, Barcelona 199203, Spain
[2] CIBERESP, Pamplona, Spain
[3] Int Agcy Res Canc Lyon, Lyon, France
[4] Merck & Co Inc, Global Hlth Outcomes, Barcelona, Spain
关键词
Human papillomavirus; Cervical cancer; Genotype; Epidemiology; Human papillomavirus vaccines; HUMAN-IMMUNODEFICIENCY-VIRUS; CANCER PREVENTION; LESIONS; TRENDS; INFECTIONS; ADENOCARCINOMA; ATTRIBUTION; EXPRESSION; BURDEN;
D O I
10.1186/1750-9378-7-38
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV vaccine currently under development. Methods: Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections of new ICC cases. Results: RC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31/33/45/52/58. Regional variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas (SCC) and 95.5% in adenocarcinomas (ADC). HPV 16/18/45 were detected in 94.2% of ADC. RC of the 9 types altogether decreased with age (trend test p < 0.0001), driven by the decrease in older ages of HPV 16/18/45. In contrast, the RC of HPV 31/33/52/58 increased with age. Due to population growth alone, projected estimates of ICC cases attributable to the 9 types are expected to rise from 493,770 new cases in 2012 to 560,887 new cases in 2025. The RCs of individual high risk HPV types varied by cytological and histological grades of HPV-positive precancerous cervical lesions, and there was an under representation of HPV 18 and 45 compared to ICC. Conclusions: The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide. If the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.
引用
收藏
页数:13
相关论文
共 38 条
[1]  
[Anonymous], 2010, GLOBOCAN 2008 V1 2 C
[2]  
[Anonymous], HUM PAP VACC WHO POS
[3]   Incidence trends of adenocarcinoma of the cervix in 13 European countries [J].
Bray, F ;
Carstensen, B ;
Moller, H ;
Zappa, M ;
Zakelj, MP ;
Lawrence, G ;
Hakama, M ;
Weiderpass, E .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (09) :2191-2199
[4]  
Brotherton JML, 2011, EXPERT REV ANTI-INFE, V9, P627, DOI [10.1586/eri.11.78, 10.1586/ERI.11.78]
[5]   Members of the human papillornavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix [J].
Clifford, Gary ;
Franceschi, Silvia .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (07) :1684-1685
[6]   Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study [J].
de Sanjose, Silvia ;
Quint, Wim G. V. ;
Alemany, Laia ;
Geraets, Daan T. ;
Ellen Klaustermeier, Jo ;
Lloveras, Belen ;
Tous, Sara ;
Felix, Ana ;
Eduardo Bravo, Luis ;
Shin, Hai-Rim ;
Vallejos, Carlos S. ;
Alonso de Ruiz, Patricia ;
Lima, Marcus Aurelho ;
Guimera, Nuria ;
Clavero, Omar ;
Alejo, Maria ;
Llombart-Bosch, Antonio ;
Cheng-Yang, Chou ;
Alejandro Tatti, Silvio ;
Kasamatsu, Elena ;
Iljazovic, Ermina ;
Odida, Michael ;
Prado, Rodrigo ;
Seoud, Muhieddine ;
Grce, Magdalena ;
Usubutun, Alp ;
Jain, Asha ;
Hernandez Suarez, Gustavo Adolfo ;
Estuardo Lombardi, Luis ;
Banjo, Aekunbiola ;
Menendez, Clara ;
Javier Domingo, Efren ;
Velasco, Julio ;
Nessa, Ashrafun ;
Chichareon, Saibua C. Bunnag ;
Qiao, You Lin ;
Lerma, Enrique ;
Garland, Suzanne M. ;
Sasagawa, Toshiyuki ;
Ferrera, Annabelle ;
Hammouda, Doudja ;
Mariani, Luciano ;
Pelayo, Adela ;
Steiner, Ivo ;
Oliva, Esther ;
Meijer, Chris J. L. M. ;
Al-Jassar, Waleed Fahad ;
Cruz, Eugenia ;
Wright, Thomas C. ;
Puras, Ana .
LANCET ONCOLOGY, 2010, 11 (11) :1048-1056
[7]   Human Papillomavirus, Human Immunodeficiency Virus and Immunosuppression [J].
Denny, Lynette A. ;
Franceschi, Silvia ;
de Sanjose, Silvia ;
Heard, Isabelle ;
Moscicki, Anna Barbara ;
Palefsky, Joel .
VACCINE, 2012, 30 :F168-F174
[8]   Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine [J].
Garland, Suzanne M. ;
Steben, Marc ;
Sings, Heather L. ;
James, Margaret ;
Lu, Shuang ;
Railkar, Radha ;
Barr, Eliav ;
Haupt, Richard M. ;
Joura, Elmar A. .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (06) :805-814
[9]   Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications [J].
Goldie, Sue J. ;
O'Shea, Meredith ;
Diaz, Mireia ;
Kim, Sun-Young .
REPRODUCTIVE HEALTH MATTERS, 2008, 16 (32) :86-96
[10]   Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer [J].
Guan, Peng ;
Howell-Jones, Rebecca ;
Li, Ni ;
Bruni, Laia ;
de Sanjose, Silvia ;
Franceschi, Silvia ;
Clifford, Gary M. .
INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (10) :2349-2359